Presently, antibodies against PD-1 and PD-L1 have been approved for treatment in a number of different cancer types [7–9]; however, the objective response rates to these inhibitors vary according to the type of tumor, ranging from 15 to 87% [10, 11]. This evidence concerns the gene CD274 and neoplasm.